Clinical Trial

Chemotherapy and Sequential Immunotherapy for Locally Advanced Urothelial Cancer

Study acronym: CHASIT
Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated September 8, 2023 (before its estimated April 2025 completion). Its status may not reflect the trial's current state.
Summary
Patients with locally advanced or clinically node positive urothelial carcinoma treated with chemotherapy, will receive 3 cycles of avelumab, followed by radical surgery.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2022-10-26.
Status change: Not Yet Recruiting → Recruiting 2023-09-06
Trial Details
NCT Number NCT05600127
Lead Sponsor Erasmus Medical Center
Collaborators: Merck KGaA, Darmstadt, Germany
Conditions Urothelial Carcinoma
Enrollment 64 participants
Start Date 2022-12-01
Primary Completion 2025-04 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2023-09-08